T5	Exp 182 201	the collective name
T6	Exp 488 511	their ester derivatives
T7	Exp 327 349	The active ingredients
T8	Exp 360 386	the pharmacological effect
T9	Exp 637 667	their anti-inflammatory effect
T10	Exp 604 607	how
T11	Exp 519 534	these compounds
T12	Exp 669 671	We
T13	Exp 682 686	that
T14	Exp 858 863	which
T15	Exp 880 893	the compounds
T16	Exp 829 844	This difference
T17	Exp 1128 1150	its inhibitory subunit
T18	Exp 1004 1009	which
T19	Exp 1358 1370	the activity
T20	Exp 1325 1340	This inhibition
T21	Exp 1453 1455	We
T22	Exp 1461 1465	that
T23	Exp 1516 1548	the active NF-kappaB heterodimer
T24	Exp 1577 1606	the NF-kappaB/IkappaB complex
T25	Exp 1619 1630	the release
T26	Exp 1744 1749	which
T27	Exp 1688 1716	the anti-inflammatory effect
T28	Exp 1643 1653	These data
R7	Coref Anaphora:T6 Antecedent:T29
R8	Coref Anaphora:T9 Antecedent:T30
R9	Coref Anaphora:T14 Antecedent:T31
R10	Coref Anaphora:T18 Antecedent:T32
R11	Coref Anaphora:T17 Antecedent:T33
R12	Coref Anaphora:T26 Antecedent:T34
T1	Protein 1408 1413	Oct-1
T2	Protein 1415 1418	TBP
T3	Protein 1420 1423	Sp1
T29	Exp 398 420	sesquiterpene lactones
T30	Exp 608 630	sesquiterpene lactones
T31	Exp 848 856	efficacy
T32	Exp 993 1002	NF-kappaB
T33	Exp 1093 1108	phosphorylation
T34	Exp 1720 1742	sesquiterpene lactones
